Experts explain: What the FDA’s approval of a new Alzheimer’s drug means for healthcare

(Credit: Unsplash)

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Kate Whiting, Senior Writer, Formative Content

  • Alzheimer’s was the seventh biggest cause of death globally in 2019.
  • The first Alzheimer’s treatment in almost 20 years has just been approved by the US Food & Drug Administration.
  • Biogen’s Aduhelm (aducanumab) targets the plaques that contribute to the cognition decline seen in dementia.
  • The infusion has divided the scientific community over its effectiveness, while research is still ongoing.
  • But it could spur investment leading to more drugs coming to market in the future.
  • Two experts explain the approval process and what it means for global healthcare.

In 2019, Alzheimer’s disease was the seventh biggest cause of death globally, so it’s likely you know someone who has been affected. It’s the leading cause of death in the UK, where, of the COVID-19 deaths in March to April 2020, 1 in 5 were people with dementia.

While there are treatments for many of the other main causes of death worldwide, there’s not been an effective therapy to slow the gradual destruction of memory and thinking skills Alzheimer’s causes.

So the announcement on 7 June that the United States Food & Drug Administration (FDA) had granted accelerated approval to the first new treatment for Alzheimer’s in almost 20 years was considered a breakthrough, particularly as cases are rising as the global population ages.

Symptoms usually appear when people are in their mid-sixties – and by 2050, 1 in 6 people will be aged over 65. It also affects women disproportionately, with women making up 65% of those who die from Alzheimer’s and other forms of dementia, according to the World Health Organization (WHO).

Future of Health and Healthcare Global Health Healthy Futures Mental Health Healthcare Delivery
Alzheimer’s was the seventh biggest cause of death globally in 2019, and is the main cause of death in the UK. Image: WHO

While the ‘accelerated approval’ of Biogen’s Aduhelm (aducanumab) infusion has divided the scientific community over its effectiveness, based on the data gathered so far, shares of US-based biotech firm Biogen and its Japanese drugmaker partner Eisai soared.

It’s not a magic bullet, with more research needed on whether it slows the decline in cognition, and it’s also expensive – at $56,000 for a yearly course.

Dr Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, told Reuters the accelerated approval pathway “allows for there being some residual uncertainty on the drug’s clinical benefits while making the drug available to patients rather than having to wait”.

Last year, the World Economic Forum launched the Davos Alzheimer’s Collaborative (DAC), a first-of-its-kind global effort to speed up progress on the discovery, testing and delivery of precision interventions for Alzheimer’s by creating a global innovation ecosystem.

Here, Forum experts, Elissa Prichep and Kelly McCain, from Shaping the Future of Health and Healthcare, explain why the new Alzheimer’s drug is significant and how the FDA approval process works.

What is the World Economic Forum doing to combat Alzheimer’s?

Alzheimer’s Diesease, a result of rapid ageing that causes dementia, is a growing concern. Dementia, the seventh leading cause of death worldwide, cost the world $1.25 trillion in 2018, and affected about 50 million people in 2019. Without major breakthroughs, the number of people affected will triple by 2050, to 152 million.

To catalyse the fight against Alzheimer’s, the World Economic Forum is partnering with the Global CEO Initiative (CEOi) to form a coalition of public and private stakeholders – including pharmaceutical manufacturers, biotech companies, governments, international organizations, foundations and research agencies.

The initiative aims to advance pre-clinical research to advance the understanding of the disease, attract more capital by lowering the risks to investment in biomarkers, develop standing clinical trial platforms, and advance healthcare system readiness in the fields of detection, diagnosis, infrastructure and access.

Why is it so important to find a treatment for Alzheimer’s?

McCain: Alzheimer’s is a looming global health crisis. It’s one we know is fast approaching and devastating to both economies and families, with 60% of the global Alzheimer’s and dementia burden in low and middle-income countries. In those countries, it not only impacts the person with the disease, it impacts their entire family structure, because you have much more of a society of caregiving, especially for women that oftentimes will have to leave the workforce to care for these individuals. Currently, the global cost of Alzheimer’s and dementia is about $1 trillion.

Nearly 90% of the world’s population that suffers from Alzheimer’s and dementia is yet to be engaged with current screening and care practices that may help spot signs or risk factors of Alzheimer’s and dementia early, and course-correct. So, when you think about what is the actual global burden and what needs to be solved, [the Biogen drug] is a massive lift. But while this is a massive scientific discovery, there’s still so much work to be done. If you think about diabetes or cancer, if you get it early, outcomes are good. But for Alzheimer’s and dementia, which is one of the top 10 causes of death worldwide, it’s the only one that cannot be prevented, slowed or cured. It’s a slow, demoralizing, economically draining death.

It’s a slow, demoralizing, economically draining death. —Kelly McCain, Project Lead, Shaping the Future of Health and Healthcare

What are the R&D phases that new drugs go through before reaching the market?

Prichep: When a product in research shows enough promise to have an impact on a disease, the sponsor will submit an Investigational New Drug (IND) application to the FDA and begin human clinical trials.

Phase 1 trials involve a small number of healthy people, and are really designed to ensure the safety of the product as a first step. The second phase continues to emphasize safety, with a focus on efficacy as well. These trials typically involve hundreds of people to get preliminary data on whether the product works on their disease.

If the product shows effectiveness, the next step is phase 3 trials, which can include thousands of people and may last several years. Phase 3 studies assess efficacy and safety of a product against a comparator, such as a placebo, in a broad sample of the patient population.

Following these trials, the sponsor submits an application to the FDA to review the data and make a decision as to whether the product is appropriate for use in the marketplace. Because Aduhelm received accelerated approval, Biogen is required to conduct phase 4 – or post approval trials – and provide the FDA with additional data on the product’s efficacy against memory loss and cognitive decline in Alzheimer’s patients.

Future of Health and Healthcare Global Health Healthy Futures Mental Health Healthcare Delivery
The three phase trials of the FDA drug approval process. Image: Food and Drug Administration

How did the approval process of the Biogen drug differ from COVID-19 vaccines?

Prichep: The FDA has different pathways to meet public needs. The emergency use authorization (EUA) issued to COVID-19 vaccines enables rapid response to public health crises. EUAs require rigorous criteria to be met but are not approvals. With products like [aducanumab], one may see accelerated approvals and fast-track approvals, which are pathways established to fill critical unmet needs in treating different diseases. So when there’s a lack of treatment options or nothing on the market that can help people with a certain condition, these pathways offer a way to get treatment out to patient populations more quickly.

The accelerated approval process allows the FDA to issue its approval based on a proxy, or what’s known as a surrogate endpoint. In this case, instead of basing approval on cognitive benefit, the FDA looked at whether this medication reduces the plaques (when protein pieces clump together) in the brain that are a contributing factor to Alzheimer’s disease. That’s what [aducanumab] was approved upon – that the medication has an impact on those plaques. That was shown in trials. Whether or not that will have a meaningful impact on cognitive decline is what we’re waiting to see from the marketplace data.

This approval is controversial. The FDA approval comes despite their Advisory Committee’s vote to not approve. So, the scientific community is not 100% on board with this product moving to market at this time. To the FDA’s credit, they’ve had expedited pathways for decades and aim to be responsive to unmet health needs of the public in a way that’s still safe and looking to ensure efficacy.

What will happen next now it’s been approved?

Prichep: Now that aducanumab has accelerated approval from the FDA, the company is able to manufacture and distribute the infusion.

What they’ll be looking to do is educate physicians on the product, ensure that there’s coverage from insurance providers, that there’s enough supply to go out to people. But what’s really important to keep in mind is the product had an accelerated approval, meaning it’s conditional.

More data needs to be collected and ultimately provided to the FDA to assess whether this is a product that is truly providing cognitive benefit in patients with Alzheimer’s disease. So what really needs to be figured out is how that data is going to be collected and used. What is the data that’s needed? And what are the timelines for that?

There’s the go-to market strategy of how does the manufacturer get this product to patients, but there’s also that really critical piece of how can the manufacturer collect the data that’s needed to validate whether this product should continue to be available to the public based on its efficacy and safety profile.

Will it then also be available in other countries besides the US?

Prichep: Countries have different regulatory processes. Some are more similar than others, but the approving regulatory authorities have different mandates and different requirements that must be met. The EU would look to do their own regulatory review before approval, as you saw with the COVID-19 vaccines.

The EU would look to do their own regulatory review before approval, as you saw with the COVID-19 vaccines. —Elissa Prichep, Project Lead, Shaping the Future of Health and Healthcare

McCain: I foresee a lot of other countries looking to the US and a system in which they are openly sharing what the data actually is and what the outcomes are. This will help some of the other countries, especially where the burden of Alzheimer’s and dementia is really high, in the low and middle-income countries. A lot is going to be dependent on how the drug performs in the US and hopefully will create a pathway for others to follow.

Are you hopeful the market reaction will encourage investment in research for other treatments?

McCain: The market responded positively to the recent approval, which is a signal that investors may be willing to invest more in science and research – and hopefully will help to reinvigorate investment in the Alzheimer’s and dementia space, and get these portfolios back on track.

Prichep: There’s been a lot of discussion and excitement about whether medications can get to market faster following the EUAs of COVID-19 vaccines. But there’s a big difference between the COVID vaccines and products like this. With diseases like Alzheimer’s, there’s still so much research that needs to go into understanding what’s really causing this disease and how to develop a targeted product that can work on it. There’s so much trial and error.

In the Alzheimer’s space, we’ve seen peaks and valleys in investment. Just a few years ago, there were numerous companies running promising trials and then the products failed to provide a benefit. Companies pulled back on investments because they couldn’t figure out how to make a product that effectively worked in Alzheimer’s disease. So, with this approval, I am hopeful for more investment and optimistic about progress, but we need to remember that finding treatments for this disease is exceedingly complicated.

What is also interesting, as I think about this approval, is the potential future use of the accelerated approval pathway. As we’re starting to understand more about genetic drivers of disease, how might companies who are looking at targeting certain genes or certain markers of a disease use this accelerated approval pathway? What is the comfort level with approving products that have yet to show clinical benefit? As we move ahead in the genetic revolution in medicine, I expect more difficult questions along those lines balanced with new opportunity to meet unmet medical needs and improve lives.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

‘Reasons to hope’ for sustainable peace in Central African Republic – UN Mission chief

We all have a ‘hierarchy of needs’. But is technology meeting them?

We want to hear about Europe our citizens are dreaming of, says von der Leyen about the upcoming Conference on the Future of Europe

European banking stress tests 2014: A more adverse approach for a shorter banking sector

EU@UNGA 74: Working towards a more peaceful, secure and prosperous world

Car clocking: MEPs call for new legislation to combat odometer fraud

20 years on from landmark Mine Ban Treaty, dangers on the rise to life and limb

Tuesday’s Daily Brief: hate speech, dementia, Libya and Yemen, human rights in Brazil and Lebanon

This new solar technology can be printed or woven into fabric

Nature is our strongest ally in ensuring global water security

China’s stock markets show recovery signs while EU is closely watching in anticipation of the €10bn investment

High-technology manufacturing saves the EU industry

This is what emerging technologies mean for the future of infrastructure

How COVID-19 compares to seasonal flu, and why you should take it seriously

Make no mistake: the purpose of business is to serve society

How teaching ‘future resilient’ skills can help workers adapt to automation

COP21 Breaking News_04 December: Launch of CREWS, climate risk & early warning systems

The Linde Group Logo (Source: The Linde Group website, Press Services, 2018)

EU starts in-depth investigation of Linde-Praxair merger over competition concerns

3 ways we are making an impact on plastic pollution

Darfur peace process at a ‘standstill’ as demonstrations against Sudanese Government continue

‘Stay together and step up’ action to meet Global Goals, ECOSOC President tells development forum

‘Ghost fishing’ is threatening our oceans. Here’s how we can tackle it

Commission assesses and sets out reform priorities for the countries aiming to join the EU

We finally have a life-saving vaccine for Ebola

An introduction to ‘Eco-Medical Literacy’ and its importance in shaping expert medical professionals

The green hydrogen revolution has started, and it won’t be stopped

COP21 Breaking News_05 December: Carbon Price Needed for Climate Change Success

Draghi’s negative interest rates help Eurozone’s cohesion

This is how flu season might affect the COVID-19 curve

The EU resumes budget support assistance to the Republic of Moldova

Bangladesh: Head of UN refugee agency calls on Asia-Pacific leaders to show ‘solidarity’ with Rohingya refugees

Will the UK really have the highest coronavirus death toll in Europe, as a US study suggests?

Coronavirus: EU guidance for a safe return to the workplace

The world is a book and those who do not travel read only one page

Faith can overcome religious nationalism. Here’s how

MEPs propose measures to combat mobbing and sexual harassment

Zero Pollution: Vast majority of Europe’s bathing waters meet the highest quality standards

State aid: Commission refers United Kingdom to European Court for failure to fully recover illegal tax exemption aid of up to around €100 million in Gibraltar

Statement on the Code of Practice against disinformation: Commission asks online platforms to provide more details on progress made

Paris, Rome, Brussels and Frankfurt to confront Berlin over growth and the Athens enigma

Tuesday’s Daily Brief: Guterres calls for restraint in Venezuela, Jazz Day, the importance of breastfeeding, and updates from Libya, Iran and Mozambique

The importance and the need of mobile technology in the health care system and in saving lives

Capital Markets Union: Commission to boost Europe’s capital markets

The EU adopted €297 million in concrete actions for refugees and local communities in Jordan and Lebanon

EU Solidarity Fund: Commission puts forward financial assistance worth €823 million for the Croatia earthquake, floods in Poland and the coronavirus crisis

Climate change will shrink these economies fastest

Mental Health in times of a pandemic: what can each individual do to lessen the burden?

Eurozone: How safe are our deposits? Which banks will survive?

Why flexible workspaces are the key to winning the talent war

We probably should go back to the therapy in Primary Healthcare

China is winning the electric vehicle race

Hurdles in the way of vaccinating one and all against COVID-19-reviewing the challenges for vaccination against COVID-19

Medical workforce migration in Europe – Is it really a problem?

Wars have rules: 5 things the UN humanitarian chief wants countries to tackle so human suffering in conflict can be minimized

The increasing drug prices in Europe

Facebook changes its terms and clarify its use of data for consumers following discussions with the European Commission and consumer authorities

Erasmus+: an expected budget of €3 billion to be invested in young Europeans and to help create European Universities in 2019

Data protection: MEPs urge the Commission to amend UK adequacy decisions

The age of influence: why digital platforms must come clean about political ads

European Union: More taxes out of less income

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s